Cytoflavin in Combination With Reperfusion in Stroke Patients

Inclusion criteria

• Signed Informed Consent;
• Men and women 18-85 y.o.;
• A diagnosis of "cerebral infarction" has been established and treatment with Cytoflavin® has already been prescribed, or other therapy has been prescribed that does not include Cytoflavin®;
• NIHSS score of at least 5 and less than 24;
• reperfusion therapy performed on admission;
• The size of the ischemic focus according to ASPECTS score >=6;
• Time from stroke onset to admission not exceeeding 6 hours;
• Start of therapy with Cytoflavin® within 24 hours from the onset of stroke (main group);
• Patients who are able to follow the procedures of the Observational Study Program and strictly follow the doctor's instructions regarding drug therapy.

Exclusion criteria

• Individual intolerance or known hypersensitivity to succinic acid, inosine, nicotinamide, riboflavin, or auxiliary components of the drug Cytoflavin®;
• Hemorrhagic stroke;
• Contraindications for CT scanning;
• Initial severe disability requiring assistance in everyday life before stroke;
• previous stroke with a residual neurological deficit;
• Severe comorbidity with a life expectancy of less than 6 months;
• Clinical or laboratory signs of an infectious disease on admission (with the exception of strokes that occurred in COVID-19 convalescents after the first 10 days of illness, and patients with asymptomatic SARS-CoV-2 infection detected during routine examination);
• Pregnancy or lactation